Evidence map›Paper›PMID 38639014›Full record

ReviewAndrology2024

Shared risk and shared responsibility: the ethics of male contraceptives.

Georgina D Campelia, Eli Y Adashi, John K Amory

Abstract readReview
In one paragraph

Review in Andrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Georgina D CampeliaDepartment of Bioethics & Humanities, Seattle, Washington, USA.
Eli Y AdashiDepartment of Medical Science, Former Dean of Medicine and Biological Sciences, Brown University, Providence, Rhode Island, USA.
John K AmoryDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.

Funding

ALDH1A1/A2 Inhibitors for Male ContraceptionR01HD098039 · NICHD · UNIVERSITY OF WASHINGTON · PI AMORY, JOHN K. · 2019 to 2023
$1.9M
NICHD NIH HHS R01 HD098039
6 · The paper itself

Abstract

introductionEfforts to develop reversible male contraceptives analogous to female oral contraceptives are underway and may be introduced in the next decade. The advent of novel male contraceptives provides an opportunity for an ethical reformulation of the contraceptive paradigm given the relational, rather than individual, nature of sexual relationships, and family planning. For individuals in any sexual relationship that could result in pregnancy, issues of reproductive autonomy, freedom, equality in reproductive decision-making and risks-both of side effects and of unintended pregnancies-are significant. Historically, however, women have been attributed the greatest responsibilities simultaneously with the most restrictions on their freedom of choice and access to reproductive care.

objectivesIn this paper, we extend our prior "shared risk" model of male contraception to one of "shared risk and responsibility" to ethically inform this discourse.

conclusionsThis updated framework more fully captures the complexity of this novel technology and may be of use to regulatory and legal agencies grappling with an intervention that poses medical risks to the member of the relationship who does not face risks of becoming pregnant.

Indexed as

Contraceptive Agents, MaleContraceptionFemaleHumansMalePregnancyContraceptive Agents, Maleautonomymale contraceptionreproductive ethicsreproductive rightsriskunintended pregnancy

Identifiers

PMID38639014
PMCPMC11461136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.